Peganone is developed by Recordati.

What development phase is Peganone in?

Peganone is FDA-approved (marketed).

What is the generic name of Peganone?

ETHOTOIN is the generic (nonproprietary) name of Peganone.

Last reviewed 2026-04-20 · How we verify

Peganone (ETHOTOIN)

Recordati · FDA-approved approved Small molecule Quality 40/100

Peganone (ETHOTOIN) is an anti-epileptic agent developed by Recordati Rare, targeting the sodium channel alpha subunit. It is a small molecule modality approved by the FDA in 1957 for treating epilepsy characterized by intractable complex partial seizures and tonic-clonic epilepsy. Peganone is off-patent, with no active Orange Book patents, and no generic manufacturers. As an off-patent medication, its commercial status is subject to change. Key safety considerations are not explicitly stated in the provided facts.

At a glance

Generic name	ETHOTOIN
Sponsor	Recordati
Drug class	Anti-epileptic Agent
Target	Sodium channel alpha subunit
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved
First approval	1957

Approved indications

Epilepsy characterized by intractable complex partial seizures
Tonic-clonic epilepsy

Common side effects

No common side effects on file.

Drug interactions

felodipine
fluorouracil
fluoxetine
fluvoxamine
phenytoin

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Peganone CI brief — competitive landscape report
Peganone updates RSS · CI watch RSS
Recordati portfolio CI